Drugs Made In America Acquisition Corp. Ordinary Shares (NASDAQ: DMAA) is a Financial Services company (Shell Companies) with a market capitalization of $265M. The Maz Rating grades it against the other companies in its sector.
Drugs Made In America Acquisition Corp. Ordinary Shares's current Maz Rating and its five factor grades are for members: log in to see them.
At $10.90, Drugs Made In America Acquisition Corp. Ordinary Shares trades at 61.8x trailing earnings. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of 3.5%, return on invested capital of -1.7% and a free cash flow yield of -0.2%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 0.02. Over the past 52 weeks the share price ranged from $10.15 to $10.91, with a beta of 0.00.
Drugs Made In America Acquisition Corp. Ordinary Shares does not currently pay a dividend.
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 0.01% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.01% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.01% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.14% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 0.01% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 0.01% / 33.33% · (Cash+Recv) / Total Assets 0.01% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of September 2026, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Drugs Made In America Acquisition Corp. Ordinary Shares is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Drugs Made In America Acquisition Corp. Ordinary Shares reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.